U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
Go back to U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA| Bank of Commerce (NASDAQ: ONC) | Delayed: 276.13 +4.33 (1.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $271.80 | 52 Week High | $0.35 | |||
| Open | $269.72 | 52 Week Low | $0.35 | |||
| Day High | $276.74 | P/E | N/A | |||
| Day Low | $269.53 | EPS | $0.00 | |||
| Volume | 331,646 | |||||
